About Erasca
Erasca is a company based in San Diego (United States) founded in 2018. Erasca has raised $300 million across 5 funding rounds from investors including Orbimed, Arch Venture Partners and TMCP. The company has 103 employees as of December 31, 2024. Erasca offers products and services including MAPKlamp and RAS Targeting Therapies. Erasca operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 103 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Erasca, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$161.65 M (USD)-29.28as on Dec 31, 2024
-
EBITDA
-$148.63 M (USD)-7.86as on Dec 31, 2024
-
Total Equity Funding
$300 M (USD)
in 5 rounds
-
Latest Funding Round
$45 M (USD), Post-IPO
Mar 27, 2024
-
Investors
Orbimed
& 11 more
-
Employee Count
103
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Erasca
Erasca is a publicly listed company on the NASDAQ with ticker symbol ERAS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Erasca
Erasca offers a comprehensive portfolio of products and services, including MAPKlamp and RAS Targeting Therapies.
Targets MAPK pathway nodes for cancer treatment
Directly inhibits RAS mutations in cancer signaling
People of Erasca
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Senior Team
10 people
Finance and Accounting
7 people
Product Management Team
5 people
Operations Team
4 people
Legal and Compliance
2 people
Data Analysis and Operations Team
2 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Erasca
Erasca has successfully raised a total of $300M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Erasca
Erasca has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and TMCP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Private equity investments in China are managed by TMCP.
|
Locked | Locked | Locked | |
|
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more
|
Locked | Locked | Locked |
Investor details for Erasca
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Erasca
Investment portfolio details for Erasca
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Erasca
Detailed financials for Erasca
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Erasca Comparisons
Peer comparison for Erasca
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Erasca
Erasca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
Detailed competitors of Erasca
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Erasca
Complete news archive for Erasca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Erasca
Erasca was founded in 2018.
Erasca is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Erasca is a funded company, having raised a total of $300M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Erasca is 103.
Erasca was founded in 2018 in San Diego, United States, within the biotechnology sector. Small molecule-based therapeutics are developed by the company to address oncology needs. Product candidates including naporafenib, ERAS-007, and ERAS-80 are advanced for melanoma and tissue-agnostic solid tumors. Operations focus on drug discovery and clinical development in the United States.
Erasca's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Erasca offers MAPKlamp and RAS Targeting Therapies.
Yes, Erasca is publicly traded on NASDAQ under the ticker symbol ERAS.
Erasca has 12 investors. Key investors include Orbimed, Arch Venture Partners, TMCP, City Hill, and Colt Ventures.
The ticker symbol of Erasca is ERAS on NASDAQ.